Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer

PURPOSE: FOLFIRINOX has demonstrated promising results for patients with pancreatic ductal adenocarcinoma (PDAC). Chemotherapy-induced immunogenic cell death can prime antitumor immune responses. We therefore performed high-dimensional profiling of immune cell subsets in peripheral blood to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Hui, James, C. Alston, Cullinan, Darren R., Hogg, Graham D., Mudd, Jacqueline L., Zuo, Chong, Takchi, Rony, Caldwell, Katharine E., Liu, Jingxia, DeNardo, David G., Fields, Ryan C., Gillanders, William E., Goedegebuure, S. Peter, Hawkins, William G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678309/
https://www.ncbi.nlm.nih.gov/pubmed/34593529
http://dx.doi.org/10.1158/1078-0432.CCR-21-0998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678309/
https://www.ncbi.nlm.nih.gov/pubmed/34593529
http://dx.doi.org/10.1158/1078-0432.CCR-21-0998

Ejemplares similares